In today’s briefing:
- IPO Databook: Immvira Bioscience (HK) – Jul 2026
IPO Databook: Immvira Bioscience (HK) – Jul 2026
- Immvira Bioscience Inc. is a clinical-stage biotechnology company focused on novel oncolytic immunotherapies and engineered exosome therapies, aiming to be a global leader in bladder cancer treatment.
- Immvira, incorporated in 2015, has a pipeline of two oncolytic immunotherapy candidates and five engineered exosome assets. MVR-T3011 received FDA Fast Track Designation for HNSCC in March 2024.
- The company reported a loss of RMB(518,861) for 2025, with net current liabilities of RMB(2,390,634) as of May 31, 2026.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
